Section 5: Patient Safety and Quality Assurance

5PSQ-053

EFFECTIVENESS AND SAFETY OF GALCANEZUMAB. REAL-LIFE RESULTS.

5PSQ-052

ANALYSIS OF POTENTIAL PROGNOSTIC FACTORS OF EFFICACY IN TISAGENLECLEUCEL TREATMENT IN A COHORT OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

5PSQ-051

EFFECTIVENESS AND SAFETY OF NIRMATRELVIR/RITONAVIR IN OLDER PATIENTS AT NURSING HOME WITH COVID-19.

5PSQ-050

IT IS POSSIBLE TO IMPROVE THE HIPOPOTASEMIC MANAGMENT IN THE HOSPITAL?

5PSQ-049

MEDICATION PRESCRIBING ERRORS PROSPECTIVE OBSERVATIONAL STUDY IN AN INTENSIVE CARE UNIT

5PSQ-048

COST-SAVING IMPACT OF USING NUSINERSEN BY CLINICAL TRIALS FOR SPINAL MUSCULAR ATROPHY

5PSQ-047

THE PERCEIVED IMPACT ON PATIENT SAFETY AND QUALITY OF CARE OF PHARMACEUTICAL TECHNICAL ASSISTANTS ON NURSING WARDS: A QUALITATIVE STUDY

5PSQ-046

SYNDROME OF INAPPROPRIATE SECRETION OF ANTIDIURETIC HORMONE INDUCED BY ALPRAZOLAM: A CASE REPORT

5PSQ-045

ANALYSIS OF A PHARMACEUTICAL INTERVENTION IN POLYMEDICATED PATIENTS WITH DEMENTIA AND IN TREATMENT WITH HIGH ANTICHOLINERGIC ACTIVITY DRUGS

5PSQ-044

SAFETY OF PEMBROLIZUMAB +/- CHEMOTHERAPY IN FIRST-LINE METASTATIC NON-SMALL-CELL LUNG CARCINOMA IN REAL-WORLD PRACTICE

5PSQ-043

DESCRIPTIVE STUDY OF MARKETED MEDICINES CONTAINING ASPARTAME

5PSQ-042

FOCUS ON MEDICATION ERRORS ON HIGH-RISK MEDICATIONS IN A HOSPITAL'S ELECTRONIC INCIDENT REPORTING SYSTEM

5PSQ-041

IMPACT OF INTRODUCING PREFILLED ATROPINE SYRINGES IN OCULAR SURGERY: PROACTIVE ASSESSMENT OF DRUG COSTS AND MEDICATION SAFETY

5PSQ-040

VOLUNTARY MEDICATION ERRORS REPORTING SYSTEM IN AN ORTHOPEDIC SURGERY AND TRAUMATOLOGY UNIT

5PSQ-039

IMPACT OF TAILORED SCREENING INTERVALS ON THE BURDEN OF DRUG-DRUG INTERACTION ALERTS: AN INTERRUPTED TIME SERIES ANALYSIS

Pages